Skip to main content
PMC home page
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2003 Dec 30;23(2):210–217. doi: 10.1002/hep.510230203

Tumor necrosis factor α gene expression and the response to interferon in chronic hepatitis C

E Larrea 1, N Garcia 1, C Qian 1, M P Civeira 1, J Prieto 1
PMCID: PMC7165845  PMID: 8591843

Abstract

Tumor necrosis factor α (TNF‐α) is a cytokine with pleiotropic properties that is induced in a variety of pathological situations including viral infections. In this work, we analyzed the expression of TNF‐α gene in patients with chronic hepatitis C. Serum TNF‐α levels were found to be elevated in all chronic hepatitis C patients including those cases presenting sustained biochemical remission of the disease after interferon therapy. Untreated patients with chronic hepatitis C showed increased TNF‐α messenger RNA (mRNA) levels in the liver and mononuclear cells as compared with healthy controls. After completion of treatment with interferon, patients experiencing sustained complete response showed values of TNF‐α mRNA, both in the liver and in peripheral mononuclear cells, within the normal range, significantly lower than patients who did not respond to interferon and than those with complete response who relapsed after interferon withdrawal. Pretreatment values of TNF‐α mRNA were lower in long‐term responders to interferon than in cases who failed to respond to the treatment. Values of TNF‐α mRNA in the liver or in mononuclear cells were higher in specimens with positive hepatitis C virus (HCV) RNA than in those samples where the virus was undetectable. Neither the intensity of the liver damage nor the amount of HCV RNA in serum or in cells showed correlation with the levels of TNF‐α transcripts in peripheral mononuclear cells but it was found that high TNF‐α values were associated with genotype 1b. In conclusion, there is an enhanced expression of TNF‐α in HCV infection. High levels of this cytokine may play a role in the resistance to interferon therapy.

References

  • 1. Camussi G, Albano E, Tetta C, Bussolino F. The molecular action of tumor necrosis factor alpha. Eur J Biochem 1991; 202: 3–14. [DOI] [PubMed] [Google Scholar]
  • 2. Cerami A. Inflammatory cytokines. Clin Immunol Immunopathol 1992; 62(suppl): S3–S10. [DOI] [PubMed] [Google Scholar]
  • 3. Nokta M, Matzke D, Jennings M, Schlick E, Nadler PI, Pollard R. In vivo administration of tumor necrosis factor‐alpha is associated with antiviral activity in human peripheral mononuclear cells. Soc Exp Biol Med 1991; 197: 144–149. [DOI] [PubMed] [Google Scholar]
  • 4. Rubin BY. TNF and viruses: multiple interrelationships In: Aggarwal BB, Vilcek J. eds. Tumor necrosis factors. New York: Dekker, 1992: 331–340. [PubMed] [Google Scholar]
  • 5. Wong GHW, Krowka JF, Stites DP, Goeddel DV. In vitro antihuman immunodeficiency virus activities of tumor necrosis factor‐alpha and interferon‐gamma. J Immunol 1988; 140: 120–125. [PubMed] [Google Scholar]
  • 6. Becker S, Quay J, Soukup J. Cytokine (tumor necrosis factor, IL‐6, and IL‐8) production by respiratory syncytial virus‐infected human alveolar macrophages. J Immunol 1991; 147: 4307–4312. [PubMed] [Google Scholar]
  • 7. Henke A, Mohr C, Sprenger H, Graebner C, Stelzner A, Nain M, Gemsa D. Coxsackievirus B3‐induced production of tumor necrosis factor‐alpha, IL‐1beta, and IL‐6 in human monocytes. J Immunol 1992; 148: 2270–2277. [PubMed] [Google Scholar]
  • 8. Gong JH, Sprenger H, Hinder F, Bender A, Schmidt A, Horch S, Nain M et al. Influenza A virus infection of macrophages enhanced tumor necrosis factor‐alpha (TNF‐α) gene expression and lipopolysaccharide‐triggered TNF‐α release. J Immunol 1991; 147: 3507–3513. [PubMed] [Google Scholar]
  • 9. Gosselin J, Flamand L, D'Addario M, Hiscott J, Menezes J. Infection of peripheral blood mononuclear cells by herpes simplex and Epstein‐Barr viruses. Differential induction of interleukin 6 and tumor necrosis factor‐alpha. J Clin Invest 1992; 89: 1849–1856. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Nagakawa J, Hishinuma I, Hirota K, Miyamoto K, Yamanaka T, Tsukidate K, Katayama K et al. Involvement of tumor necrosis factor‐alpha in the pathogenesis of activated macrophage‐mediated hepatitis in mice. Gastroenterology 1990; 99: 758–765. [DOI] [PubMed] [Google Scholar]
  • 11. Devictor D, Decimo D, Sebire G, Tardieu M, Hadchouel M. Enhanced tumor necrosis factor alpha in coronavirus but not in paracetamol‐induced acute hepatic necrosis in mice. Liver 1992; 12: 205–208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Goto M, Takei Y, Kawano S, Tsuji S, Fukui H, Fushimi H, Nishimura Y, et al. Tumor necrosis factor and endotoxin in the pathogenesis of liver and pulmonary injuries after orthotropic liver transplantation in the rat. Hepatology 1992; 16: 487–493. [DOI] [PubMed] [Google Scholar]
  • 13. Muto Y, Meager A, Eddleston ALWF, Nouri‐Aria KT, Alexander GJM, Williams R. Enhanced tumour necrosis factor and interleukin‐1 in fulminant hepatic failure. Lancet 1988; 9: 72–74. [DOI] [PubMed] [Google Scholar]
  • 14. Bird GLA, Sheron N, Goka AKJ, Alexander GJ, Williams RS. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990; 112: 917–920. [DOI] [PubMed] [Google Scholar]
  • 15. Mizuhara H, O'Neille E, Seki N, Ogawa T, Kusonoki C, Otsuka K, Satoh S, et al. T cell activation‐associated hepatic injury: mediation by tumor necrosis factor and protection by interleukin‐6. J Exp Med 1994; 179: 1529–1537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Sheron N, Lau J, Daniels H, Goka J, Eddleston A, Alexander GJM, Williams R. Increased production of tumour necrosis factor alpha in chronic hepatitis B virus infection. J Hepatol 1991; 12: 251–255. [DOI] [PubMed] [Google Scholar]
  • 17. De la Mata M, Meager A, Rolando N, Daniels HM, Nouri‐Aria KT, Goka AKJ, Eddleston ALWF, et al. Tumour necrosis factor production in fulminant hepatic failure: relation to aetiology and superimposed microbial infection. Clin Exp Immunol 1990; 82: 479–484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Yoshioka K, Kakumu S, Arao M, Tsutsumi Y, Inoue M. Tumor necrosis factor alpha production by peripheral blood mononu‐clear cells of patients with chronic liver disease. Hepatology 1989; 10: 769–773. [DOI] [PubMed] [Google Scholar]
  • 19. Tilg H, Wilmer A, Vogel W, Herold M, Nolchen B, Judmaier G, Huber Ch. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992; 103: 264–274. [DOI] [PubMed] [Google Scholar]
  • 20. Gil B, Quian C, Riezu‐Boj JI, Civeira MP, Prieto J. Hepatic and extrahepatic HCV RNA strands in chronic hepatitis C: different patterns of response to interferon treatment. Hepatology 1993; 18: 1050–1054. [PubMed] [Google Scholar]
  • 21. Qian C, Camps J, Maluenda MD, Civeira MP, Prieto J. Replication of hepatitis C virus in peripheral blood mononuclear cells, effect of alpha‐interferon therapy. J Hepatol 1992; 16: 380–383. [DOI] [PubMed] [Google Scholar]
  • 22. Fong TL, Shindo M, Feinstone SM, Hoofnagle JH, Di Bisceglie AM. Detection of replicative intermediates of hepatitis C viral RNA in liver and serum of patients with chronic hepatitis C. J Clin Invest 1991; 88: 1058–1060. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Camps J, Crisóstomo S, García‐Granero M, Riezu‐Boj JI, Civeira MP, Prieto J. Prediction of the response of chronic hepatitis C to interferon alpha: a statistical analysis of pretreatment variables. Gut 1993; 34: 1714–1717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Knodell R, Ishak K, Black W, Chen T, Craig R, Kaplowitz N, Kiernan T et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435. [DOI] [PubMed] [Google Scholar]
  • 25. Chomczynsky P, Sacchi N. Single‐step of RNA isolation by acid guanidinium thiocyanate‐phenol‐chloroform extraction. Anal Biochem 1987; 162: 156–159. [DOI] [PubMed] [Google Scholar]
  • 26. Wang AM, Creasey AA, Ladner MB, Lin LS, Strickler J, Van Arsdell JN, Yamamoto R et al. Molecular cloning of the complementary DNA for human tumor necrosis factor. Science 1985; 228: 149–154. [DOI] [PubMed] [Google Scholar]
  • 27. Ng SY, Gunning P, Eddy R, Ponte P, Leavitt J, Shows T, Kedes L. Evolution of the functional human beta‐actin gene and its multipseudogene family: conservation of noncoding regions and chromosomal dispersion of pseudogenes. Mol Cell Biol 1985; 5: 2720–2732. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Okamoto H, Okada S, Sugiyama Y, Yotsumoto T, Tanaka T, Yoshizawa H, Tsuda F et al. The 5′–terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990; 60: 167–177. [PubMed] [Google Scholar]
  • 28a. Gerson JA, Ring C, Tuke P, Tedder RS. Enhanced detection by PCR of hepatitis C virus RNA. Lancet 1990; 336: 878–879. [DOI] [PubMed] [Google Scholar]
  • 29. Simmonds P, Rose KA, Graham S, Chan SW, McOmish F, Dow BC, Follet EAC, et al. Mapping of serotype‐specific, immunodom‐inant epitopes in the NS‐4 region of hepatitis C virus (HCV): use of type‐specific peptides to serologically differentiate infections with HCV types 1, 2 and 3. J Clin Microbiol 1993; 31: 1493–1503. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Viazov S, Zibert A, Ramakrishnan K, Widell A, Cavicchini A, Schreier E, Roggendord M. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods 1994; 48: 81–92. [DOI] [PubMed] [Google Scholar]
  • 31. Peterson PK, Gekker G, Chao ChC, Hu Sh, Edelman Ch, Balfour HH, Verhoef J. Human cytomegalovirus‐stimulated peripheral blood mononuclear cells induce HIV‐1 replication via a tumor necrosis factor‐alpha‐mediated mechanism. J Clin Invest 1992; 89: 574–580. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Daniels HM, Meager A, Eddleston ALWF, Alexander GJM, Williams R. Spontaneous production of tumour necrosis factor alpha and interleukin‐lbeta during interferon‐alpha treatment of chronic HBV infection. Lancet 1990; 335: 875–877. [DOI] [PubMed] [Google Scholar]
  • 33. Gonzalez‐Amaro R, García‐Monzón C, García‐Buey L, Moreno‐Otero R, Alonso JL, Yagüe E, Pivel JP et al. Induction of tumor necrosis factor‐alpha production by human hepatocytes in chronic viral hepatitis. J Exp Med 1994; 179: 841–848. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Shinagawa T, Yoshioka K, Kakumu S, Wakita T, Ishikawa T, Itoh Y, Takayanagi M. Apoptosis in cultured rat hepatocytes: the effects of tumour necrosis factor alpha and interferon gamma. J Pathol 1991; 165: 253–257. [DOI] [PubMed] [Google Scholar]
  • 35. Adamson GM, Billings RE. Tumor necrosis factor induced oxidative stress in isolated mouse hepatocytes. Arch Biochem Biophys 1992; 294: 223–229. [DOI] [PubMed] [Google Scholar]
  • 36. Ishii Y, Partridge CA, Del Vecchio PJ, Malik AB. Tumor necrosis factor‐alpha‐mediated decrease in glutathione increases the sensitivity of pulmonary vascular endothelial cells to H202 J Clin Invest 1992; 89: 794–802. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37. Pogrebniak HW, Matthews W, Pass HI. Alterations in macrophage free radical and tumor necrosis factor production by a potassium channel activator. J Surg Res 1992; 52: 395–400. [DOI] [PubMed] [Google Scholar]
  • 38. Henkel T, Machleldt T, Alkalay I, Krönke M, Ben‐Neriah Y, Baeurle PA. Rapid proteolysis of IKB‐alpha is necessary for activation of transcription factor NF‐kB. Nature 1993; 365: 182–185. [DOI] [PubMed] [Google Scholar]
  • 39. Suarez M, Beloqui O, Ferrer JV, Gil B, Qian Ch, García N, Civeira P, et al. Glutathione depletion in chronic hepatitis C. Int Hepatol Comm 1993; 1: 215–221. [Google Scholar]
  • 40. Herrmann F, Helfrich SG, Lindemann A, Schleiermacher E, Huber Ch, Mertelsmann R. Elevated circulating levels of tumor necrosis factor predict unresponsiveness to treatment with interferon alpha‐2b in chronic myelogenous leukemia. J Clin Oncol 1992; 10: 631–634. [DOI] [PubMed] [Google Scholar]
  • 41. Mita E, Hayashi N, Hagiwara H, Ueda K, Kanazawa Y, Kasahara A, Fusamoto H et al. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer. Dig Dis Sci 1994; 39: 977–982. [DOI] [PubMed] [Google Scholar]
  • 42. Sheron N, Lau JYN, Daniels HM, Webster J, Eddleston ALWF, Alexander GJM, Williams R. Tumor necrosis factor to treat chronic hepatitis B virus infection. Lancet 1990; 336: 321–332. [DOI] [PubMed] [Google Scholar]
  • 43. Guidotti LG, Guilhot S, Chisari FV. Interleukin‐2 and alpha/ beta interferon down‐regulated hepatitis B virus gene expression in vivo by tumor necrosis factor‐dependent and‐independent pathways. J Virol 1994; 68: 1265–1270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Beloqui O, Prieto J, Suarez M, Gil B, Qian Ch, Garcia N, Civeira P. N‐Acetyl cysteine enhances the response to interferon‐alpha in chronic hepatitis C: a pilot study. J Interferon Res 1993; 13: 279–282. [DOI] [PubMed] [Google Scholar]

Articles from Hepatology (Baltimore, Md.) are provided here courtesy of Wiley

RESOURCES